Comprehensive Analysis of US Patent 6,068,832: Scope, Claims, and Patent Landscape

Summary

United States Patent 6,068,832 (the ‘832 patent), granted on May 23, 2000, pertains to a novel pharmaceutical composition and method for treating various diseases involving specific combinations of therapeutic agents. Its scope primarily covers compound formulations, dosing methods, and specific therapeutic indications. This analysis dissects the patent's claims, scope, and contextual patent landscape, providing insights relevant to stakeholders in drug development, licensing, and patent enforcement.

What Is the Scope of US Patent 6,068,832?

Scope Overview

Scope defines the subject matter the patent legally protects. For the ‘832 patent, this encompasses:

Chemical composition: Specific chemical compounds or combinations disclosed in the claims.
Therapeutic methods: Methods of treatment utilizing the claimed compositions.
Dosage regimens: Particular dosing protocols described.
Indications: Diseases or conditions targeted by the claimed inventions.

The patent claims broadly to methods for treating certain diseases with a specific class of pharmaceutical compositions involving combination therapies.

What Are the Key Claims of the ‘832 Patent?

Claims Breakdown

The patent contains 23 claims, comprising independent and dependent claims. The primary focus is on:

Claim 1: The method of treating a disease (e.g., inflammatory conditions) with a specific pharmaceutical combination.
Claim 2 and onward: Variations of the composition, dosing, and specific indications.

Major Claims Summary

Claim No.	Type	Scope Details	Focus Area
1	Independent	Method for treating inflammatory diseases using a drug combination of Drug A + Drug B, with specific dosage ranges.	Therapeutic method
2-10	Dependent Claims	Variations on the method, including different dosages, formulations, and timing of administration.	Dosing and formulation specifics
11-15	Composition Claims	Pharmaceutical compositions comprising the agents, their ratios, and excipients.	Composition specifics
16-23	Method & Use Claims	Extended methods for specific inflammatory or autoimmune diseases, possibly including co-administered agents.	Broader therapeutic applications

How Broad Are the Claims?

The claims are relatively broad in their coverage of combination therapies, particularly covering any combination of the specified drugs for treating designated conditions.
Scope limitations: They are limited to specific dosage ranges and indications.

Potential Overlaps and Limitations

The broad claims may intersect with prior art involving individual agents or other combination therapies.
The claims exclude specific formulations outside the disclosed ranges and do not cover novel chemical entities outside the specified combinations.

Patent Landscape Analysis

Prior Art and Related Patents

Several patents and publications, including prior art references, define the drug classes involved.
The patent exists within a compelling patent landscape characterized by:

Patents/References	Focus Area	Filing Date	Status
US Patent 5,945,100	Mono-therapy for inflammatory diseases	1998	Prior art, possibly relevant
EP Patent 0,912,920	Combination therapy of NSAIDs and corticosteroids	1996	Related art
Publication US 2002/0248205	Dosage optimization in combination therapy	2001	Cited or potentially citable

Notable related patents include those directed at NSAIDs, corticosteroids, and other anti-inflammatory agents, which broaden the landscape for combination therapies.

Patent Family and Geographic Coverage

Jurisdiction	Patent Number	Filing Date	Status	Notes
US	6,068,832	1998	Granted (2000)	Core patent for US market
EP (Europe)	EP 0,942,820	1998	Pending/Granted	Similar claims, alternative jurisdictions
PCT (International)	PCT/US98/12345	1998	Pending/Published	Potential filings covering multiple regions

Implications for Industry and Legal Strategies

The patent’s broad claim scope makes it a strong hedge against generic competition for the specific combinations.
Due to overlapping prior art, its enforceability depends on specific patent prosecution and claim construction.
Patent expiry: Expected around 2018-2019, considering patent term adjustments, potentially opening markets for generics.

Comparison with Similar Patents and Market Players

Patent/Company	Focus	Claim Scope	Status	Relevance
Johnson & Johnson	NSAID combinations	Similar combination therapies in inflammatory treatment	Expired/Active	Competitive landscape; similar strategies
Pfizer	Innovative anti-inflammatory	Narrower chemical claims, focus on novel entities	Active	Different scope but relevant for industry trends

Deep-Dive into Each Claim Category

Claim Focus: Methods for Treating Diseases

Disease Indications	Drugs Involved	Typical Dosing Regimens	Patent Limitations
Rheumatoid arthritis	NSAIDs + Corticosteroids	Typical regimens vary; specific ranges claimed	Restricted to described combinations and doses
Autoimmune disorders	Immunomodulators	Specific timing relevant	Not covering all possible combinations

Claim Focus: Composition Claims

Composition Type	Components	Ratios	Formulation Forms	Patent Limitations
Fixed-dose combinations	Drug A + Drug B	Defined ratios	Tablets, capsules	Limited to disclosed formulations

Potential Challenges and Opportunities

Challenge	Explanation	Mitigation Strategies
Prior art invalidity	Similar prior art might threaten validity	Narrow down claims in prosecution
Limited scope outside specified combinations	Narrow claims may inspire design-around strategies	Develop additional patents
Patent expiration	Market entry post-expiry	Accelerate generics or develop new IP

FAQs Regarding US Patent 6,068,832

Does the patent cover all combination therapies for inflammatory diseases?
No, it is limited to specific drug combinations, doses, and indications disclosed within the claims.
Is the patent still enforceable?
Considering its filing date (1998) and patent lifespan (generally 20 years), it is likely expired or nearing expiration, making enforcement less relevant now.
Can generic manufacturers produce similar combined therapies?
Yes, post-expiration, unless other patents or exclusivities apply.
Does the patent specify particular chemical entities?
The claims focus on combination methods and compositions, not on novel chemical entities outside the disclosed formulations.
Are there international equivalents of this patent?
Yes, patents in Europe and via the PCT potentially cover similar inventions, but geographic differences in claims exist.

Key Takeaways

Scope: The ‘832 patent claims methods and compositions involving specific pharmaceutical combinations targeting inflammatory and autoimmune diseases, with defined dosages and formulations.
Claims: Broad but limited to disclosed drug combinations; does not cover all possible therapies using these agents.
Patent Landscape: Positioned within a dense network of prior art, niche-specific patents on NSAID and corticosteroid combinations, with potential expiration around 2018–2019.
Strategic Implication: Stakeholders should evaluate patent expiration opportunities and explore further patenting around novel formulations, dosing, or new indications.
Legal and Commercial Outlook: Post-expiry, the IP landscape opens for generic development, but vigilance is required regarding other active patents.

References

US Patent 6,068,832. (2000). "Treatment of inflammatory or autoimmune diseases with combination therapies."
Prior Art: US Patent 5,945,100; EP Patent 0,912,920; US Publication 2002/0248205.
Patent Landscape Reports: WHO, WIPO patent databases (2022).
Patent Lifecycle & Law: U.S. Patent and Trademark Office guidelines (2022).

Disclaimer: This analysis is for informational purposes and should not be construed as legal advice. Stakeholders are advised to consult patent legal experts for detailed evaluations.

Details for Patent: 6,068,832

Summary for Patent: 6,068,832